Radhika Avadhani1, Kristen Fowler1, Corinne Barbato1, Sherine Thomas1, Winnie Wong1, Camille Paul1, Mehmet Aksakal1, Thomas H Hauser2, Katie Weinger3, Allison B Goldfine4. 1. Joslin Diabetes Center, Boston, Mass. 2. Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Harvard University, Boston, Mass. 3. Joslin Diabetes Center, Boston, Mass; Harvard Medical School, Harvard University, Boston, Mass. 4. Joslin Diabetes Center, Boston, Mass; Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Harvard University, Boston, Mass. Electronic address: allison.goldfine@joslin.harvard.edu.
Abstract
OBJECTIVE: Higher hemoglobin A1c (HbA1c) is associated with lower cognitive function in type 2 diabetes. To determine whether associations persist at lower levels of dysglycemia in patients who have established cardiovascular disease, cognitive performance was assessed in the Targeting INflammation Using SALsalate in CardioVascular Disease (TINSAL-CVD) trial. METHODS: The age-adjusted relationships between HbA1c and cognitive performance measured by the Mini-Mental State Examination, Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test, Trail Making Test, and Categorical Verbal Fluency were assessed in 226 men with metabolic syndrome and established stable coronary artery disease. RESULTS: Of the participants, 61.5% had normoglycemia, 20.8% had impaired fasting glucose, and 17.7% had type 2 diabetes. HbA1c was associated with cognitive function tests of Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test, Trail Making Test, and Categorical Verbal Fluency (all P < .02), but not the Mini-Mental State Examination. In an age-adjusted model, a 1% (11 mmol/mol) higher HbA1c value was associated with a 5.9 lower Digit Symbol Substitution Test score (95% confidence interval [CI], -9.58 to -2.21; P < .0001); a 2.44 lower Rey Auditory Verbal Learning Test score (95% CI, -4.00 to -0.87; P < .0001); a 15.6 higher Trail Making Test score (95% CI, 5.73 to 25.6; P < .0001); and a 3.71 lower Categorical Verbal Fluency score (95% CI, -6.41 to -1.01; P < .02). In a multivariate model adjusting for age, education, and cardiovascular covariates, HbA1c remained associated with cognitive function tests of Rey Auditory Verbal Learning Test (R(2) = 0.27, P < .0001), Trail Making Test (R(2) = 0.18, P < .0001), and Categorical Verbal Fluency (R(2) = 0.20, P < .0001), although association with the Digit Symbol Substitution Test was reduced. CONCLUSIONS: Higher HbA1c is associated with lower cognitive function performance scores across multiple domain tests in men with metabolic syndrome and coronary artery disease. Future studies may demonstrate whether glucose lowering within the normative range improves cognitive health.
OBJECTIVE: Higher hemoglobin A1c (HbA1c) is associated with lower cognitive function in type 2 diabetes. To determine whether associations persist at lower levels of dysglycemia in patients who have established cardiovascular disease, cognitive performance was assessed in the Targeting INflammation Using SALsalate in CardioVascular Disease (TINSAL-CVD) trial. METHODS: The age-adjusted relationships between HbA1c and cognitive performance measured by the Mini-Mental State Examination, Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test, Trail Making Test, and Categorical Verbal Fluency were assessed in 226 men with metabolic syndrome and established stable coronary artery disease. RESULTS: Of the participants, 61.5% had normoglycemia, 20.8% had impaired fasting glucose, and 17.7% had type 2 diabetes. HbA1c was associated with cognitive function tests of Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test, Trail Making Test, and Categorical Verbal Fluency (all P < .02), but not the Mini-Mental State Examination. In an age-adjusted model, a 1% (11 mmol/mol) higher HbA1c value was associated with a 5.9 lower Digit Symbol Substitution Test score (95% confidence interval [CI], -9.58 to -2.21; P < .0001); a 2.44 lower Rey Auditory Verbal Learning Test score (95% CI, -4.00 to -0.87; P < .0001); a 15.6 higher Trail Making Test score (95% CI, 5.73 to 25.6; P < .0001); and a 3.71 lower Categorical Verbal Fluency score (95% CI, -6.41 to -1.01; P < .02). In a multivariate model adjusting for age, education, and cardiovascular covariates, HbA1c remained associated with cognitive function tests of Rey Auditory Verbal Learning Test (R(2) = 0.27, P < .0001), Trail Making Test (R(2) = 0.18, P < .0001), and Categorical Verbal Fluency (R(2) = 0.20, P < .0001), although association with the Digit Symbol Substitution Test was reduced. CONCLUSIONS: Higher HbA1c is associated with lower cognitive function performance scores across multiple domain tests in men with metabolic syndrome and coronary artery disease. Future studies may demonstrate whether glucose lowering within the normative range improves cognitive health.
Authors: Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; James Schmeidler; Jeremy M Silverman; Mary Sano; Keren Koifmann; Rachel Preiss; Hadas Hoffman; Anthony Heymann; Michal Schnaider Beeri Journal: Int J Geriatr Psychiatry Date: 2013-08-08 Impact factor: 3.485
Authors: W Q Qiu; D M Walsh; Z Ye; K Vekrellis; J Zhang; M B Podlisny; M R Rosner; A Safavi; L B Hersh; D J Selkoe Journal: J Biol Chem Date: 1998-12-04 Impact factor: 5.157
Authors: Richard H Tuligenga; Aline Dugravot; Adam G Tabák; Alexis Elbaz; Eric J Brunner; Mika Kivimäki; Archana Singh-Manoux Journal: Lancet Diabetes Endocrinol Date: 2013-12-19 Impact factor: 32.069
Authors: Mônica M Teixeira; Valéria M A Passos; Sandhi M Barreto; Maria I Schmidt; Bruce B Duncan; Alline M R Beleigoli; Maria J M Fonseca; Pedro G Vidigal; Larissa F Araújo; Maria de Fátima H S Diniz Journal: Sci Rep Date: 2020-01-31 Impact factor: 4.379
Authors: I K Wium-Andersen; J Rungby; M B Jørgensen; A Sandbæk; M Osler; M K Wium-Andersen Journal: Epidemiol Psychiatr Sci Date: 2019-08-28 Impact factor: 6.892